Role of cytokines in pulmonary antimicrobial host defense

Immunologic Research

Volumn 20, Issue 1, 1999, Pages 15-27

  Mehrad, Borna ^a,b   Standiford, Theodore J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Chemokines; Cytokines; Imnnunotherapy; Infectious immunity; Lung; Pneumonia

Indexed keywords

CYTOKINE;

BACTERIAL INFECTION; HOST RESISTANCE; HUMAN; INFLAMMATION; LUNG INFECTION; MYCOSIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW;

EID: 0032787624     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02786504     Document Type: Review

References (115)

1. 1 Murray JF: The Normal Lung: The Basis for Diagnosis and Treatment of Pulmonary Disease. Philadelphia, Saunders, 1986.
2. 2 Garibaldi RA: Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact. Am J Med 1985;78:32-37.
3. 3 Anonymous. Statistical Abstract of the United States. Washington DC, U. S. Department of Commerce, Bureau of Census, 1988.
4. 4 Pinner RW, Teutsch SM, Simonsen L, Klug LA, Graber JM, Clarke MJ, et al.: Trends in infectious diseases mortality in the United States. JAMA 1996;275:189-193.
5. 5 Holmberg SD, Solomon SL, Blake PA: Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987;9:1065-1078.
6. 6 Reynolds HY: Normal and defective respiratory host defences; in Pennington, JE (ed): Respiratory Infections - Diagnosis and Management. New York, Raven Press, 1994, pp 1-34.
7. 7 Jackson AE, Southern PM, Pierce AK, Fallis BD, Sanford JP: Pulmonary clearance of gram-negative bacilli. J Lab Gin Med 1967; 69:833-841.
8. 8 Toews GB: Pulmonary clearance of infectious agents; in Pennington, JE (ed): Respiratory Infections -Diagnosis and Managment. New York, Raven, 1994, pp 43-53.
9. 9 Le J, Vilcek J: Tumor necrosis factor and interleukin I: cytokines with multiple overlapping biological activities. Lab Invest 1987;56: 234-248.
10. 10 Beutler B: TNF, immunity and inflammatory disease: lessons of the past decade. J Invest Med 1995;43:227-235.
11. 11 Tan AM, Ferrante A, Goh DH, Roberton DM, Cripps AW: Activation of the neutrophil bactericidal activity for nontypable Haemophilus influenzae by tumor necrosis factor and lymphotoxin. Pediatr Res 1995;37:155-159.
12. 12 Oswald IP, Wynn TA, Sher A, James SL: Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation. Proc Natl Acad Sci USA 1992;89:8676-8680.
13. 13 Huffnagle GB, Toews GB, Burdick MD, Boyd MB, McAllister KS, McDonald RA, et al.: Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 1996;157:4529-4536.
14. 14 Dehoux MS, Boutten A, Ostinelli J, Seta N, Dombret MC, Crestani B, et al.: Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994;150: 710-716.
15. 15 van der Poll T, Keogh CV, Buurman WA, Lowry SF: Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice. Am J Respir Crit Care Med 1997;155:603-608.
16. 16 Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K: Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 1997;65:257-260.
17. 17 Laichalk LL, Kunkel SL, Strieter RM, Danforth JM, Bailie MB, Standiford TJ: Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. Infect Immun 1996; 64:5211-5218.
18. 18 Gosselin D, DeSanctis J, Boule M, Skamene E, Matouk C, Radzioch D: Role of tumor necrosis factor alpha in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infect Immun 1995;63:3272-3278.
19. 19 Brieland JK, Remick DG, Freeman PT, Hurley MC, Fantone JC, Engleberg NC: In vivo regulation of replicative Legionella pneumophila lung infection by endogenous tumor necrosis factor alpha and nitric oxide. Infect Immun 1995;63:3253-3258.
20. 20 Mehrad B, Strieter RM, Standiford TJ: Role of TNF in pulmonary host defense in murine invasive aspergillosis. J Immunol 1999;162: 1633-1640
21. 21 Kolls JK, Beck JM, Nelson S, Summer WR, Shellito J: Alveolar macrophage release of tumor necrosis factor during murine Pneumocystis carinii pneumonia. Am J Respir Cell Mol Biol 1993; 8:370-376.
22. 22 Standiford TJ, Wilkowski JM, Sisson TH, Hattori N, Mehrad B, Bucknell KA, Moore TA: Intrapulmonary tumor necrosis factor gene therapy increases bacterial clearance and survival in murine gram-negative pneumonia. Hum Gene Ther 1999;10:899-909
23. 23 Laichalk LL, Bucknell KA, Huffnagle GB, Wilkowski JM, Moore TA, Romanelli RJ, et al.: Intrapulmonary delivery of tumor necrosis factor agonist peptide augments host defense in murine gram-negative bacterial pneumonia. Infect Immun 1998;66:2822-2826.
24. 24 Standiford TJ, Kunkel SL, Greenberger MJ, Laichalk LL, Strieter RM: Expression and regulation of chemokines in bacterial pneumonia. J Leukoc Biol 1996;59:24-28.
25. 25 Huffnagle GB, Strieter RM, Kunkel SL, Toews GB, Standiford TJ : The role of chemokines in pneumonia; in Koch, A, Strieter, RM (eds): Chemokines in Disease. Austin, R. G. Landes, 1996, pp 151-168.
26. 26 Strieter RM, Kunkel SL: Chemokines; in Crystal, RG, West, JB, Weibel, ER, Barnes, PJ (eds): The Lung: Scientific Foundations. Philadelphia, Lippincott-Raven, 1996, pp 155-186.
27. 27 Baggiolini M, Dewald B, Moser B: Human chemokines: an update. Annu Rev Immunol 1997;15: 675-705.
28. 28 Rodriguez JL, Miller CG, DeForge LE, Kelty L, Shanley CJ, Bartlett RH, et al.: Local production of interleukin-8 is associated with nosocomial pneumonia. J Trauma 1992;33:74-81; discussion 81-72.
29. 29 Benfield TL, Vestbo J, Junge J, Nielsen TL, Jensen AB, Lundgren JD: Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995; 151: 1058-1062.
30. 30 Johnson MC, 2nd, Kajikawa O, Goodman RB, Wong VA, Mongovin SM, Wong WB, et al.: Molecular expression of the alpha-chemokine rabbit GRO in Escherichia coli and characterization of its production by lung cells in vitro and in vivo. J Biol Chem 1996;271: 10,853-10,858.
31. 31 Kooguchi K, Hashimoto S, Kobayashi A, Kitamura Y, Kudoh I, Wiener-Kronish J, et al.: Role of alveolar macrophages in initiation and regulation of inflammation in Pseudomonas aeruginosa pneumonia. Infect Immun 1998;66: 3164-3169.
32. 32 Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Laichalk LL, McGillicuddy DC, et al.: Neutralization of macrophage inflammatory protein-2 attenuates neutro-phil recruitment and bacterial clearance in tnurine Klebsiella pneumonia. J Infect Dis 1996;173:159-165.
33. 33 Tsai WC, Strieter RM, Wilkowski JM, Bucknell KA, Burdick MD, Lira SA, et al.: Lung-specific transgenic expression of KC enhances resistance to Klebsiella pneumoniae in mice. J Immunol 1998; 161:2435-2440.
34. 34 Gao JL, Wynn TA, Chang Y, Lee EJ, Broxmeyer HE, Cooper S, et al.: Impaired host defense, hematopoiesis, granulomatous inflammation and type I-type 2 cylokine balance in mice lacking CC chemokine receptor I. J Exp Med 1997; 185:1959-1968.
35. 35 Huffhagle GB, Strieter RM, Standiford TJ, McDonald RA, Burdick MD, et al.: The role of monocyte chemotactic protein-1 (MCP-1) in the recruitment of monocytes and CD4+ T cells during a pulmonary Cryptococcus neoformans infection. J Immunol 1995;155:4790-4797.
36. 36 Huffnagle GB, Strieter RM, McNeil LK, McDonald RA, Burdick MD, Kunkel SL, et al.: Macrophage inflammatory protein-1alpha (MIP-1alpha) is required for the efferent phase of pulmonary cell-mediated immunity to a Cryptococcus neoformans infection. J Immunol 1997; 159:318-327.
37. 37 Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-2357.
38. 38 Romagnani S: Biology of human TH1 and TH2 cells. J Clin Immunol 1995;15:121-129.
39. 39 Allen JE, Maizels RM: Th1-Th2: reliable paradigm or dangerous dogma? Immunol Today 1997;18: 387-392.
40. 40 Billiau A: Interferon-gamma: biology and role in pathogenesis. Adv Immunol 1996;62:61-130.
41. 41 Boehm U, Klamp T, Groot M, Howard JC: Cellular responses to interferon-gamma. Annu Rev Immunol 1997;15:749-795.
42. 42 Gallin JI, Farber JM, Holland SM, Nutman TB: Interferon-gamma in the management of infectious diseases. Ann Intern Med 1995;123: 216-224.
43. 43 The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991;324: 509-516.
44. 44 Kolls JK, Nelson S, Summer WR: Recombinant cytokines and pulmonary host defense. Am J Med Sci 1993;306:330-335.
45. 45 Appelberg R: Protective role of interferon gamma, tumor necrosis factor alpha and interleukin-6 in Mycobacterium tuberculosis and M. avium infections. Immunobiology 1994;191:520-525.
46. 46 Lovchik JA, Lyons CR, Lipscomb MF: A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am J Respir Cell Mol Biol 1995;13:116-124.
47. 47 Hoag KA, Street NE, Huffnagle GB, Lipscomb MF: Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am J Respir Cell Mol Biol 1995;13:487-495.
48. 48 Garvy BA, Ezekowitz RA, Harmsen AG: Role of gamma interferon in the host immune and inflammatory responses to Pneumocystis carinii infection. Infect Immun 1997;65:373-379.
49. 49 Beck JM, Liggitt HD, Brunette EN, Fuchs HJ, Shellito JE, Debs RJ: Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon. Infect Immun 1991;59:3859-3862.
50. 50 Skerrett SJ, Martin TR: Intratracheal interferon-gamma augments pulmonary defenses in experimental legionellosis. Am J Respir Crit Care Med 1994;149:50-58.
51. 51 Tsai WC, Strieter RM, Zisman DA, Wilkowski JM, Bucknell KA, Chen GH, et al.: Nitric oxide is required for effective innate immunity against Klebsiella pneumoniae. Infect Immun 1997; 65: 1870-1875.
52. 52 Zisman DA, Strieter RM, Kunkel SL, Tsai WC, Wilkowski JM, Bucknell KA, et al.: Ethanol feeding impairs innate immunity and alters the expression of Th1-and Th2-phenotype cytokines in murine Klebsiella pneumonia. Alcohol Clin Exp Res 1998;22: 621-627.
53. 53 Greenberger MJ, Kunkel SL, Strieter RM, Lukacs NW, Bramson J, Gauldie J, et al.: IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 1996;157:3006-3012.
54. 54 Rubins JB, Pomeroy C: Role of gamma interferon in the pathogenesis of bacteremic pneumococcal pneumonia. Infect Immun 1997;65:2975-2977.
55. 55 Johansen HK, Hougen HP, Rygaard J, Hoiby N: Interferon-gamma (IFN-gamma) treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats. Clin Exp Immunol 1996;103:212-218.
56. 56 Kolls JK, Lei D, Nelson S, Summer WR, Shellito JE: Pulmonary cytokine gene therapy. Adenoviral-mediated murine interferon gene transfer compartmentally activates alveolar macrophages and enhances bacterial clearance. Chest 1997;111:104S.
57. 57 Kolls JR, Lei D, Stoltz D, Zhang P, Schwarzenberger PO, Ye P, et al.: Adenoviral-mediated interferon-gamma gene therapy augments pulmonary host defense of ethanol-treated rats. Alcohol Clin Exp Res 1998;22:157-162.
58. 58 Trinchieri G, Gerosa F: Immunoregulation by interleukin-12. J Leukoc Biol 1996;59:505-511.
59. 59 Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A: Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T cell-deficient hosts [see comments]. Proc Natl Acad Sci USA 1993;90:6115-6119.
60. 60 Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MR: Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993; 177: 1505-1509.
61. 61 Flynn JL, Goldstein MM, Triebold KJ, Sypek J, Wolf S, Bloom BR: IL-12 increases resistance of BALB/ c mice to Mycobacterium tuberculosis infection. J Immunol 1995; 155:2515-2524.
62. 62 Stevenson MM, Tam MF, Wolf SF, Sher A: IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism. J Immunol 1995; 155:2545-2556.
63. 63 Wagner RD, Steinberg H, Brown JF, Czuprynski CJ: Recombinant interleukin-12 enhances resistance of mice to Listeria monocytogenes infection. Microb Pathog 1994;17:175-186.
64. 64 Cooper AM, Roberts AD, Rhoades ER, Callahan JE, Getzy DM, Orme IM: The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 1995;84:423-432.
65. 65 Zhou P, Sieve MC, Bennett J, Kwon-Chung KJ, Tewari RP, Gazzinelli RT, et al.: IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma. J Immunol 1995;155:785-795.
66. 66 Kawakami K, Tohyama M, Xie Q, Saito A: IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococrus neuformans. Clin Exp Immunol 1996;104:208-214.
67. 67 Romani L, Puccetti P, Bistoni F: Interleukin-12 in infectious diseases. Clin Microbiol Rev 1997; 10:611-636.
68. 68 Laichalk LL, Danforth JM, Standiford TJ: Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol Med Microbiol 1996;15:181-187.
69. 69 Ralph P, Nakoinz I, Sampson-Johannes A, Fong S, Lowe D, et al.: IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992;148:808-814.
70. 70 Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G: Interleukin 10 (1L-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 1993;178:2207-2211.
71. 71 Kasama T, Strieter RM, Lukacs NW, Burdick MD, Kunkel SL: Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994;152:3559-3569.
72. 72 de Vries JE: Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med 1995; 27:537-541.
73. 73 Howard M, Muchamuel T, Andrade S, Menon S: Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993;177: 1205-1208.
74. 74 Standiford TJ, Strieter KM, Lukacs NW, Kunkel SL: Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 1995;155:2222-2229.
75. 75 Cox G: IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis of neutrophils. Am J Physiol 1996; 271:L566-571.
76. 76 Mulligan MS, Jones ML, Vaporciyan AA, Howard MC, Ward PA: Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J Immunol 1993;151:5666-5674.
77. 77 Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Goodman RE, Standiford TJ: Neutralization of IL-10 increases survival in amurine model of Klebsiella pneumonia. J Immunol 1995;155:722-729.
78. 78 van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SF: Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996;174:994-1000.
79. 79 Vecchiarelli A, Retini C, Monari C, Tascini C, Bistoni F, Kozel TR: Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun 1996; 64:2846-2849.
80. 80 Yang X, HayGlass KT, Brunham RC: Genetically determined differences in IL-10 and IFN-gamma responses correlate with clearance of Chlamydia trachomatis mouse pneumonitis infection. J Immunol 1996;156:4338-4344.
81. 81 Bermudez LE, Champsi J: Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Infect Immun 1993; 61:3093-3097.
82. 82 Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Strieter RM, Standiford TJ: Interleukin 10 is a major mediator of sepsis-induced impairment in lung antimicrobial host defense. J Immunol 1999;162:392-399.
83. 83 Sawa T, Corry DB, Gropper MA, Ohara M, Kurahashi K, Wiener-Kronish JP: IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J Immunol 1997;159:2858-2866.
84. 84 Huffnagle GB: Role of cytokines in T cell immunity to a pulmonary Cryptococcus neoformans infection. Biol Signals 1996;5:215-222.
85. 85 Huffnagle GB, Boyd MB, Street NE, Lipscomb MF: IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J Immunol 1998;160: 2393-2400.
86. 86 Kanaly ST, Hines SA, Palmer GH: Cytokine modulation alters pulmonary clearance of Rhodococcus equi and development of granulomatous pneumonia. Infect Immun 1995;63:3037-3041.
87. 87 Jain-Vora S, LeVine AM, Chroneos Z, Ross GF, Hull WM, Whitsett JA: Interleukin-4 enhances pulmonary clearance of Pseudomonas aeruginosa. Infect Immun 1998;66:4229-4236.
88. 88 Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP: The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127-137.
89. 89 Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78.
90. 90 Kopf M, Baumann H, Freer G, Freudenherg M, Lamers M, Kishimoto T, et al.: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994;368:339-342.
91. 91 Hack CE, De Groot ER, FeltBersma RJ, Nuijens JH, Strack Van Schijndel RJ, et al.: Increased plasma levels of interleukin-6 in sepsis [see comments]. Blood 1989; 74:1704-1710.
92. 92 Bonten MJ, Froon AH, Gaillard CA, Greve JW, de Leeuw PW, Drent M, et al.: The systemic inflammatory response in the development of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156:1105-1113.
93. 93 Lieberman D, Livnat S, Schlaeffer F, Porath A, Horowitz S, Levy R: IL-1 beta and IL-6 in community-acquired pneumonia: bacteremic pneumococcal pneumonia versus Mycoplasma pneumoniae pneumonia. Infection 1997;25:90-94.
94. 94 Buck C, Bundschu J, Gallati H, Bartmann P, Pohlandt F: Interleukin-6: a sensitive parameter for the early diagnosis of neonatal bacterial injection. Pediatrics 1994; 93:54-58.
95. 95 Kuster H, Weiss M, Willeitner AE, Detlefsen S, Jeremias I, Zbojan J, et al.: Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation [in process citation]. Lancet 1998; 352:1271-1277.
96. 96 Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK: IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101:311-320.
97. 97 Dalrymple SA, Lucian LA, Slattery R, McNeil T, Aud DM, Fuchino S, et al.: Interleukin-6-deficient mice are highly susceptible 10 Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect Immun 1995; 63:2262-2268.
98. 9H Dalrymple SA, Slattery R, Aud DM, Krishna M, Lucian LA, Murray R: Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun 1996;64:3231-3235.
99. 99 van der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M, Lowry SF: Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 1997;176:439-444.
100. 100 Nelson S: Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the nonneutropenic host: an overview. Clin Infect Dis 1994; 18 Suppl 2:S197-204.
101. 101 Pauksen K, Elfman L, Ulfgren AK, Venge P: Serum levels of granulocyte-colony stimulating factor (G-CSF) in bacterial and viral infections, and in atypical pneumonia. Br J Haematol 1994; 88:256-260.
102. 102 Tazi A, Nioche S, Chastre J, Smiejan JM, Hance AJ: Spontaneous release of granulocyte colony-stimulating factor (G-CSF) by alveolar macrophages in the course of bacterial pneumonia and sarcoidosis: endotoxin-dcpendent and endotoxin-independent G-CSF release by cells recovered by bronchoalveolarlavage. Am J Respir Cell Mol Biol 1991;4:140-147.
103. 103 Bermudez LE, Young LS: Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex. J Leukoc Biol 1990;48:67-73.
104. 104 Blanchard DK, Michelini-Norris MB, Pearson CA, McMillen S, Djeu JY: Production of granulocyte-macrophage colony-stimulating factor (GM-CSF) by monocytes and large granular lymphocytes stimulated with Mycobacterium avium-M. intracellulare: activation of bactericidal activity by GM-CSF. Infect Immun 1991;59:2396-2402.
105. 105 Denis M: Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M, avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukoc Biol 1991; 49:380-387.
106. 106 Chen GH, Curtis JL, Mody CH, Christensen PJ, Armstrong LR, Toews GB: Effect of granulocyte-macrophage colony-stimulating factor on rat alveolar macrophage anticryptococcal activity in vitro. J Immunol 1994;152:724-734.
107. 107 Levitz SM: Activation of human peripheral blood mononuclcar cells by interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans. Infect Immun 1991;59: 3393-3397.
108. 108 Hebert JC, O'Reilly M: Granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances pulmonary defenses against pneumococcal infections after splenectomy. J Trauma 1996;41:663-666.
109. 109 Mandujano JF, D'Souza NB, Nelson S, Summer WR, Beckerman RC, Shellito JE: Granulocyte-macrophage colony stimulating factor and Pneumocystis carinii pneumonia in mice. Am J Respir Crit Care Med 1995;151:1233-1238.
110. 110 Lister PD, Gentry MJ, Preheim LC: Granulocyte colony-stimulating factor protects control rats but not ethanol-fed rats from fatal pneumococcal pneumonia. J Infect Dis 1993;168:922-926.
111. 111 Preheim LC, Snitily MU, Gentry MJ: Effects of granulocyte colony-stimulating factor in cirrhotic rats with pneumococcal pneumonia. J Infect Dis 1996; 174:225-228.
112. 112 Nelson S, Summer W, Bagby G, Nakamura C, Stewart L, Lipscomb G, et al.: Granulocyte colony-slimulating factor enhances pulmonary host defenses in normal and ethanol-treated rats. J Infect Dis 1991; 164:901-906.
113. 113 Smith WS, Sumnicht GE, Sharpe RW, Samuelson D, Millard FE: Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. Blood 1995;86:1301-1309.
114. 114 Freeman BD, Quezado Z, Zeni F, Natanson C, Danner RL, Banks S, et al.: rG-CSF reduces endotoxemia and improves survival during E. coli pneumonia. J Appl Physiol 1997;83:1467-1475.
115. 115 Nelson S, Belknap SM, Carlson RW, Dale D, DeBoisblanc B, Farkas S, et al.: A randomized controlled trial of filgrastim as an adjunct 10 antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. J Infect Dis 1998; 178:1075-1080.